Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9973895 | 1.00 | P2RX7 (0.42) | P2RX7GPBAR1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL9934707 | 0.84 | UBE2N (0.43) | GPBAR1ALDH1A1HSD17B10KDM4EMEN1 | |
| SCHEMBL9934211 | 0.82 | NOTUM (0.42) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL9933959 | 0.82 | NOTUM (0.42) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL9933955 | 0.82 | NOTUM (0.42) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL9973897 | 0.82 | TSHR (0.59) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL9933624 | 0.82 | KMT2A (0.44) | GPBAR1ALDH1A1KDM4ETSHRKMT2A | |
| SCHEMBL9934231 | 0.81 | KMT2A (0.55) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL9934664 | 0.79 | MAPT (0.51) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL9973900 | 0.79 | MAPT (0.42) | GPBAR1ALDH1A1HSD17B10KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885GPBAR1 26/4885ALDH1A1 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.